Lumito AB and Katana Labs GmbH sign Letter of Intent and enter into a strategic partnership to enhance biomarker detection and quantification
Lumito AB (publ) ("Lumito" or the "Company") today announces that the Company and Katana Labs GmbH (“Katana Labs”) have signed a Letter of Intent (“LOI) formalising a strategic partnership to jointly commercialise an end-to-end, ultra-sensitive immunohistochemistry (IHC) workflow that integrates Lumito’s labelling and scanning technology with Katana Labs’ AI-powered image analysis platform. This is a result of the first phase of the collaboration, which was successful, after which the companies now strengthen the commercial collaboration.
Lumito and Katana Labs will develop and jointly commercialise an end-to-end, ultra-sensitive immunohistochemistry (IHC) workflow that integrates Lumito’s up-converting nanoparticle (UCNP)-based imaging technology with Katana Labs’ advanced AI-powered image analysis platform. The strategic collaboration aims to deliver a fully integrated ultra-sensitive IHC platform for enhanced tissue analysis and reliable biomarker detection, addressing critical unmet research needs in IHC e.g. the detection and quantification of low/ultralow expressed biomarkers such as HER2. Users can implement the end-to-end workflow in-house or access it as scanning-as-a-service.
The LOI precedes a non-exclusive agreement under which both parties will continue their independent commercial activities. At the same time, they will collaborate to further validate and promote their combined end-to-end workflow through co-marketing and joint commercialisation efforts. By presenting each other’s solutions in customer meetings and shared presentations, both companies aim to expand market exposure and provide CRO and biopharma R&D customers with an integrated, all-in-one workflow solution, from labeling kit to scanner and cloud-based image analysis.
